Post by "Pop" Stran on May 5, 2005 16:09:47 GMT -5
Bextra has joined Vioxx on the bench but Celebrex is still in the game.
The Food and Drug Administration (FDA) Thursday yanked Bextra from the market, citing evidence that the COX-2 painkiller's risks outweigh its benefits.
Public Citizen flailed away at the agency, accusing it of being "reckless" in leaving Celebrex on the market.
It said all three drugs share common risks...although we have of course noticed and noted that Celebrex outsells Bextra nearly 2-1...Isn't money always the common denominator?
The Food and Drug Administration (FDA) Thursday yanked Bextra from the market, citing evidence that the COX-2 painkiller's risks outweigh its benefits.
Public Citizen flailed away at the agency, accusing it of being "reckless" in leaving Celebrex on the market.
It said all three drugs share common risks...although we have of course noticed and noted that Celebrex outsells Bextra nearly 2-1...Isn't money always the common denominator?